Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Imago BioSciences, Inc.IMGO · Entity 15490 | 10% owner | July 20, 2021 | July 20, 2021 |
| Iterum Therapeutics plcITRM · Entity 72802 | 10% owner | January 21, 2020 | January 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Imago BioSciences, Inc.
Report date July 20, 2021 · Filed July 20, 2021
Jointly reported with Heron Patrick J, FHM VII, L.L.C., Frazier Healthcare VII, L.P., Frazier Healthcare VII-A, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 41,582 |
Reported balance
After 2021-07-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-07-20 · Purchase · Acquired 41,582 · Balance 41,582 F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 145,918 |
Reported balance
After 2021-07-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-07-20 · Purchase · Acquired 145,918 · Balance 145,918 F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 383,514 |
Reported balance
After 2021-07-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-07-20 · Conversion · Acquired 341,932 · Balance 383,514 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 594,583 |
Reported balance
After 2021-07-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-07-20 · Conversion · Acquired 211,069 · Balance 594,583 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 658,943 |
Reported balance
After 2021-07-20 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-07-20 · Conversion · Acquired 64,360 · Balance 658,943 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,345,808 |
Reported balance
After 2021-07-20 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-07-20 · Conversion · Acquired 1,199,890 · Balance 1,345,808 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,086,481 |
Reported balance
After 2021-07-20 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2021-07-20 · Conversion · Acquired 740,673 · Balance 2,086,481 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,312,331 |
Reported balance
After 2021-07-20 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2021-07-20 · Conversion · Acquired 225,850 · Balance 2,312,331 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-07-20 · Conversion · Disposed 341,932 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-07-20 · Conversion · Disposed 1,199,890 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-07-20 · Conversion · Disposed 211,069 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-07-20 · Conversion · Disposed 740,673 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-07-20 · Conversion · Disposed 64,360 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-07-20 · Conversion · Disposed 225,850 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any.
F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any.
F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date.
Iterum Therapeutics plc
Report date January 21, 2020 · Filed January 23, 2020
Jointly reported with Frazier Healthcare VII, L.P., Frazier Healthcare VII-A, L.P., FHM VII, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 6.500% Exchangeable Senior Subordinated Note due 2025SEC Table II · derivative / convertible security · Expires 2025-01-31 | Direct | 1,167,000 |
Reported balance
After 2020-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-21 · Grant · Acquired 1,167,000 · Balance 1,167,000 F1: On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). F2: The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms. F3: The Exchangeable Note is held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the securities held by FH VII. FHM VII, L.P. and FHM VII, L.L.C. disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of its pecuniary interest therein, if any. |
| 6.500% Exchangeable Senior Subordinated Note due 2025SEC Table II · derivative / convertible security · Expires 2025-01-31 | Direct | 333,000 |
Reported balance
After 2020-01-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-21 · Grant · Acquired 333,000 · Balance 333,000 F1: On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). F2: The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms. F4: The Exchangeable Note is held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C. FHM VII, L.P. and FHM VII, L.L.C. disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share).
F2: The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms.
F3: The Exchangeable Note is held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the securities held by FH VII. FHM VII, L.P. and FHM VII, L.L.C. disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of its pecuniary interest therein, if any.
F4: The Exchangeable Note is held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C. FHM VII, L.P. and FHM VII, L.L.C. disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of its pecuniary interest therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANAPTYSBIO, INC
Report date May 11, 2018 · Filed May 15, 2018
Jointly reported with Frazier Healthcare VII, L.P., Frazier Healthcare VII-A, L.P., FHM VII, L.L.C., FRAZIER ALAN D, Naini Nader J, Every Nathan R, Heron Patrick J
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 973,612 |
Reported balance
After 2018-05-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-11 · Other · Disposed 1,372,000 · Balance 973,612 F1: Effective May 11, 2018, Frazier Healthcare V, L.P., distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by Frazier Healthcare V, L.P. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 11, 2018, Frazier Healthcare V, L.P., distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by Frazier Healthcare V, L.P. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionSeries C Preferred Stock · Derivative | 225,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · derivative · entry 14 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 225,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionSeries B Preferred Stock · Derivative | 740,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · derivative · entry 13 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 740,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionSeries A Preferred Stock · Derivative | 1,199,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · derivative · entry 12 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,199,890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionSeries C Preferred Stock · Derivative | 64,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · derivative · entry 11 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 64,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionSeries B Preferred Stock · Derivative | 211,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · derivative · entry 10 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 211,069 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionSeries A Preferred Stock · Derivative | 341,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · derivative · entry 9 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 341,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F3 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionCommon Stock | 225,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 8 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,312,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionCommon Stock | 740,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 7 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,086,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionCommon Stock | 1,199,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 6 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,345,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionCommon Stock | 64,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 5 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 658,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionCommon Stock | 211,069 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 4 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 594,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | ConversionCommon Stock | 341,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 3 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 383,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | PurchaseCommon Stock | 145,918 | $16.00 | $2,334,688.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 145,918 F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 20, 2021 Filed Jul 20, 2021 21:54 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | PurchaseCommon Stock | 41,582 | $16.00 | $665,312.00 |
DisclosureSEC source: 0001567619-21-013730 · doc1.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 41,582 F1 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:34 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Grant6.500% Exchangeable Senior Subordinated Note due 2025 · Derivative | 333,000 | $333,000.00 | $110,889,000,000.00 |
DisclosureSEC source: 0001012975-20-000050 · edgar.xml · derivative · entry 2 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,000 Underlying: Ordinary Shares · 333,000 shares Expires 2025-01-31 F1 · derivative.exercise_price: On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). F2 · derivative.exercise_price: The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms. F2 · derivative.exercise_date: The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms. F4 · ownership.direct: The Exchangeable Note is held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C. FHM VII, L.P. and FHM VII, L.L.C. disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:34 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Grant6.500% Exchangeable Senior Subordinated Note due 2025 · Derivative | 1,167,000 | $1,167,000.00 | $1,361,889,000,000.00 |
DisclosureSEC source: 0001012975-20-000050 · edgar.xml · derivative · entry 1 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167,000 Underlying: Ordinary Shares · 1,167,000 shares Expires 2025-01-31 F1 · derivative.exercise_price: On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). F2 · derivative.exercise_price: The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms. F2 · derivative.exercise_date: The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms. F3 · ownership.direct: The Exchangeable Note is held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the securities held by FH VII. FHM VII, L.P. and FHM VII, L.L.C. disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries B-2 Preferred Shares · Derivative | 44,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · derivative · entry 14 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII-A, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 44,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F4 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F6 · derivative.expiration_date: Not applicable. F5 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries B-1 Preferred Shares · Derivative | 53,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · derivative · entry 13 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII-A, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 53,899 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F3 · derivative.exercise_date: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F6 · derivative.expiration_date: Not applicable. F5 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries A Preferred Shares · Derivative | 141,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · derivative · entry 12 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII-A, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 141,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F1 · derivative.exercise_date: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F6 · derivative.expiration_date: Not applicable. F5 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries B-2 Preferred Shares · Derivative | 157,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · derivative · entry 11 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 157,701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F4 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F6 · derivative.expiration_date: Not applicable. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries B-1 Preferred Shares · Derivative | 189,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · derivative · entry 10 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 189,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F3 · derivative.exercise_date: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F6 · derivative.expiration_date: Not applicable. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries A Preferred Shares · Derivative | 495,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · derivative · entry 9 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 495,370 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F1 · derivative.exercise_date: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F6 · derivative.expiration_date: Not applicable. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 101,150 | $13.00 | $1,314,950.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 8 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII-A, L.P. Disclosed balance after: 341,155 F5 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 44,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 7 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII-A, L.P. Disclosed balance after: 240,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F5 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 53,899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 6 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII-A, L.P. Disclosed balance after: 195,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F5 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 141,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 5 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII-A, L.P. Disclosed balance after: 141,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F5 · ownership.nature: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 354,949 | $13.00 | $4,614,337.00 |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 4 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII, L.P. Disclosed balance after: 1,197,161 F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 157,701 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 3 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII, L.P. Disclosed balance after: 842,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 189,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII, L.P. Disclosed balance after: 684,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 30, 2018 Filed May 30, 2018 21:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 495,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034197 · doc4.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VII, L.P. Disclosed balance after: 495,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2 · ownership.nature: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 11, 2018 Filed May 15, 2018 18:25 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | OtherCommon Stock | 1,372,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-18-000437 · edgar.xml · nonDerivative · entry 1 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 973,612 F1 · kind: Effective May 11, 2018, Frazier Healthcare V, L.P., distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by Frazier Healthcare V, L.P. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F1 · ownership.nature: Effective May 11, 2018, Frazier Healthcare V, L.P., distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by Frazier Healthcare V, L.P. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 17:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | OtherWarrants · Derivative | 117,235 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001012975-17-000092 · edgar.xml · derivative · entry 2 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 117,235 shares Expires 2018-11-04 F1 · derivative.exercise_date: This warrant is exercisable at any time. F2 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 17:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | OtherCommon Stock | 117,235 | $4.55 | $533,419.25 |
DisclosureSEC source: 0001012975-17-000092 · edgar.xml · nonDerivative · entry 1 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,345,612 F2 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries D Preferred Stock · Derivative | 209,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · derivative · entry 12 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 209,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F4 · derivative.exercise_date: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F4 · derivative.expiration_date: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F7 · derivative.underlying_shares: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F7 · ownership.nature: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries D Preferred Stock · Derivative | 733,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · derivative · entry 11 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 733,740 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F4 · derivative.exercise_date: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F4 · derivative.expiration_date: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F6 · derivative.underlying_shares: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F6 · ownership.direct: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries C-1 Preferred Stock · Derivative | 195,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · derivative · entry 10 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 195,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F3 · derivative.exercise_date: The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F3 · derivative.expiration_date: The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F5 · derivative.underlying_shares: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries C Preferred Stock · Derivative | 604,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · derivative · entry 9 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 604,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F2 · derivative.exercise_date: The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F2 · derivative.expiration_date: The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F5 · derivative.underlying_shares: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries B Preferred Stock · Derivative | 1,428,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · derivative · entry 8 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,428,571 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F5 · derivative.underlying_shares: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F5 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 88,709 | $15.00 | $1,330,635.00 |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · nonDerivative · entry 7 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 88,709 F7 · shares: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F7 · ownership.nature: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 311,291 | $15.00 | $4,669,365.00 |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · nonDerivative · entry 6 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,291 F6 · shares: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F6 · ownership.direct: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 209,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · nonDerivative · entry 5 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 209,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F4 · price: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F7 · ownership.nature: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 733,740 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · nonDerivative · entry 4 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F4 · price: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F6 · ownership.direct: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 195,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · nonDerivative · entry 3 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 195,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F3 · price: The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F5 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 604,055 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · nonDerivative · entry 2 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 604,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F2 · price: The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F5 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 16:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 1,428,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-17-000071 · edgar.xml · nonDerivative · entry 1 Frazier Healthcare VII, L.P. · CIK 0001553071 · 10% owner Frazier Healthcare VII-A, L.P. · CIK 0001575192 · 10% owner FHM VII, L.P. · CIK 0001654632 · 10% owner FHM VII, L.L.C. · CIK 0001654631 · 10% owner FRAZIER ALAN D · CIK 0001018534 · 10% owner Naini Nader J · CIK 0001344203 · 10% owner Every Nathan R · CIK 0001531105 · 10% owner Heron Patrick J · CIK 0001365617 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,428,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. F1 · price: The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date. F5 · ownership.nature: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.